Physician profile
Shaheed Khan
NPI 1427066414
$9,243.44
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $1,054 · 2021: $1,312 · 2022: $1,427 · 2023: $1,479 · 2024: $2,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,480 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.04 |
| Education | $142.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,546.11 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,477.05 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,027.19 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $866.63 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $718.14 | 2019-2024 | Verquvo, Steglatro |
| Sanofi-Aventis U.S. LLC | $516.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $508.91 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $446.81 | 2022-2024 | |
| Lilly USA, LLC | $398.74 | 2020-2024 | Zepbound, Mounjaro, Jardiance |
| Amarin Pharma, INC. | $292.54 | 2019-2021 | |
| Mannkind Corporation | $183.62 | 2019-2024 | Afrezza |
| Glaxosmithkline, LLC. | $178.93 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $110.26 | 2021-2022 | |
| Esperion Therapeutics, INC. | $103.52 | 2023-2024 | Nexletol |
| Exact Sciences Corporation | $102.92 | 2023-2024 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $79.99 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $79.28 | 2019-2024 | Eliquis |
| Eisai INC. | $78.34 | 2023-2024 | |
| Shield Therapeutics INC | $67.96 | 2023-2024 | Accrufer |
| Arbor Pharmaceuticals, INC. | $61.97 | 2020-2021 | |
| Allergan, INC. | $61.95 | 2020 | |
| Horizon Therapeutics Plc | $61.06 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $59.74 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.83 | 2019 | |
| Abbott Laboratories | $30.28 | 2022 | |
| Insulet Corporation | $29.30 | 2024 | Omnipod |
| Dexcom, INC. | $24.11 | 2023 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $22.85 | 2023 | Edarbyclor |
| Lexicon Pharmaceuticals, INC. | $22.67 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $19.65 | 2019 | |
| Si-Bone, INC. | $18.10 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaheed Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.